Eighty-three serum specimens from 24 patients infected with Candida albicans were examined for circulating Candida protein antigens with the Candida Detection System (CAND-TEC; Ramco Laboratories, Inc., Houston, Tex.). The medical records of each patient were reviewed for clinical evidence of Candida colonization or disease, predisposing factors for infection, underlying illness, the presence of a contaminated indwelling venous catheter, intravenous amphotericin B therapy, and outcome. Forty-nine serum specimens with antigen titers of 1:2 or less were obtained either from colonized patients or at a time when disseminated disease was not yet clinically suspected. Except for five specimens from two colonized patients, one with a contaminated arterial line, the other specimens with titers of 1:8 or greater (n = 14) were obtained from patients who had been clinically diagnosed and treated for disseminated candidiasis. Serum specimens with titers of 1:4 were often from patients with deep-seated candidal infection but were not uniformly diagnostic; in this situation additional specimens should be tested for Candida antigen titers. Only 1 of 24 serum specimens from patients with no evidence of C. albicans infection had a Candida protein antigen titer of 1:8. With a 1:8 or greater titer as a criterion for dissemination, the sensitivity of the CAND-TEC system was 71%, with a specificity of 98%. If the 1:8 titer for the colonized patient with a contaminated arterial line is not considered a false-positive result, the CAND-TEC sensitivity was 83%. The latex agglutination assay appears to be a useful, rapid, and noninvasive means of laboratory diagnosis of systemic candidiasis. The recovery of C. albicans from at least three body sites may also be a useful predictor of disseminated disease.
With increasing therapeutic modalities available for medical care, the incidence of systemic candidiasis has increased. For example, in leukemic patients, Candida infection rates observed at autopsy increased from 2% for the period 1963 to 1970 to 35% for the period 1971 to 1975 (9) . Trauma, broad-spectrum and multiple narrow-spectrum antimicrobic coverage, steroid therapy, carbohydrate-rich diets, and indwelling urinary or intravenous (i.v.) catheterization are factors which predispose individuals to candidiasis (12) .
The diagnosis of deep-seated Candida infections is difficult. Only 15 to 40% of patients with postmortem evidence of disseminated candidiasis were treated premortem for the disease (3) . Presently, diagnosis of disseminated candidiasis is primarily clinical. Definitive confirmation is by histopathologic demonstration of candidal invasion of visceral tissue (4) . Laboratory diagnosis of candidiasis has included culture, antibody detection, and antigen detection.
Isolation of Candida albicans from clinical specimens must be interpreted with caution. This is especially true with hospitalized patients who have a higher Candida colonization rate than do healthy individuals. For example, oral and fecal C. albicans prevalence is approximately 10% for normal adults and 20% or higher for hospitalized patients (12) . The isolation frequency of C. albicans is 15% for vaginal specimens from healthy women and 10% for urine specimens; it is isolated infrequently from skin samples from normal subjects and at a variable rate from sputum specimens (12) . Blood cultures are positive for only 44% of patients with autopsy-proven candidiasis (11) . Conversely, candidemia does not always lead to systemic disease (15) . Fungal surveillance cultures also are not good predictors of systemic C. albicans infections (13) . However, multiple positive cultures do correlate with systemic C. tropicalis infections (13) .
Serodiagnostic methods for detecting antibodies to Candida spp. have included counterimmunoelectrophoresis, double diffusion, immunoelectrophoresis, immunofluorescence, radioimmunoassay, and enzyme-linked immunosorbent assay (3, 12) . The sensitivity of these assays in diagnosing systemic candidiasis has ranged from 50 to 92% for immunocompetent patients, with an even lower sensitivity of detection for immunosuppressed patients (3, 8) . These assays, however, lack specificity in distinguishing between colonization and deep-seated invasion (3) .
The insensitivity of antibody detection in immunosuppressed patients has led to serodiagnostic tests for circulating Candida antigens. The Candida antigen examined in most of these assays is mannan, the major component of Candida cell walls. Although mannan antigenemia is detected at higher rates in immunosuppressed patients than antibodies are (9) , the sensitivity is still only 50 to 70% (3, 9) . Increased detection might be obtained if the mannans of both C. albicans serotypes (A and B) were used. Serotype A accounts for 74% of the clinical isolates of C. albicans (1) .
Candidal metabolites such as mannose and arabinitol have been detected in serum by gas-liquid chromatography. When the arabinitol-to-creatine ratio in serum was examined, the sensitivity and specificity of diagnosing invasive candidiasis were 64 and 96%, respectively (6) .
Recently, a commercially available latex agglutination test distinguish between patients with deep-seated candidiasis and those colonized with C. albicans.
MATERIALS AND METHODS
Serum specimens. Serum specimens from 24 patients with C. albicans isolated from one or more sites and from 24 patients with no fungus isolated from at least 10 specimens were examined for circulating Candida antigens. The serum specimens obtained were those that had been submitted for blood chemistry tests. The serum specimens were stored at 1 to 8°C for not more than 6 days before Candida protein antigen testing.
Isolation and identification of C. albicans. Specimens requested for routine bacteriological or fungal cultures or both were processed as outlined in the Manual of Clinical Microbiology (14) . Yeasts were identified as C. albicans either by demonstration of germ tube production at 3 h of incubation in serum at 35°C (14) or by assimilation profiles with the API 20C System (Analytab Products, Plainview, N.Y.).
Candida antigen detection. Circulating Candida protein antigens were detected in serum with the Candida Detection System, CAND-TEC (Ramco Laboratories, Inc., Houston, Tex.). Sera were diluted 1:2 with the diluent supplied in the kit. The diluted specimen (20 ,ul) was mixed with 20 ,ul of latex particle coated with rabbit anti-Candida antibody. The mixture was rotated at 140 rpm for 10 min in a moist chamber and then read immediately for agglutination. Specimens with positive screens at 1:2 for Candida antigen were further titrated by using twofold serial dilutions. The endpoint was read as the highest dilution with positive agglutination.
Circulating mannan antigen was detected with the LACandida Antigen Detection System (Immuno-Mycologics, Inc., Norman, Okla.). Patient serum (300 ,ul) was mixed with 50 ,ul of detacher enzyme and incubated at 56°C for 15 min, and the reaction was stopped by the addition of an enzyme inhibitor. The detacher enzyme is a proteolytic enzyme which destroys antibodies associated in immune complexes, thus liberating mannan antigen for detection. The treated sera were tested undiluted and at a 1:10 dilution by mixing 2 drops of serum with 1 drop of latex particle sensitized with rabbit anti-Candida globulin. After the mixture was rotated at 160 rpm for 5 min in a moist chamber, the agglutination was read immediately. A low Candida mannan antigen control is included in the system kit. The control does not have to be treated with detacher enzyme or enzyme inhibitor before testing with sensitized latex reagent.
Patient groups. Patients were divided into two groups based on whether C. albicans had or had not been isolated. To determine whether the C. albicans isolated was causing disease, patient charts were reviewed for (i) clinical observations made by the attending physician, (ii) evidence of predisposing factors for Candida infection, such as underlying illness, use of antimicrobial agents, hyperalimentation, and catheterization, (iii) evidence of i.v. catheterization, (iv) evidence of i.v. amphotericin B therapy, (v) outcome, and (vi) in those cases in which postmortems were performed, histopathological results. Clinical impressions were based on microbiological findings, the presence of predisposing factors for Candida colonization and dissemination, patient clinical history, and patient progress with antimicrobial or other therapeutic approaches.
RESULTS
Serum specimens from 24 patients with cultures positive for C. albicans were tested for circulating candidal antigen. A clinical or histopathological diagnosis of systemic or deep-seated candidiasis was made for six patients (patients 1 through 6; Table 1 arterial line contaminated with C. albicans. C. albicans was isolated from specimens taken from multiple sites in 18 of the 24 patients. Five of the six patients with disseminated disease had C. albicans isolated from three or four body sites. Patient 5 with pericardial candidiasis had C. albicans isolated premortem from two sites. Four patients (patients 11, 13, 20, and 21) with C. albicans colonization had the yeast isolated from three body sites, whereas the 14 other patients with C. albicans colonization had the organisms isolated from one or two sites.
The titers of circulating Candida antigen for each patient from whom C. albicans was isolated are presented in Table  2 . Of the 83 serum specimens tested from these 24 patients, 36 exhibited no agglutination with the Candida latex reagent. Of the 36 seronegative serum specimens, 34 were obtained from colonized patients. Two serum specimens with no detectable Candida antigen were from patients with disseminated disease; one was obtained from patient 1 early during hospitalization, 6 days before any C. albicans culture-isolation, and one was obtained from patient 4 10 days after i.v. amphotericin B therapy. Thirteen serum specimens had a 1:2 titer of circulating candidal antigen; six were from colonized patients, and seven were from three patients (patients 1, 2, and 5) with deep-seated candidiasis. The single serum sample from patient 1 with a 1:2 titer was obtained 1 day before any C. albicans culture isolation. The four serum specimens from patient 2 with 1:2 titers were obtained more than 1 week before clinical suspicions of disseminated disease and i.v. amphotericin B therapy; one serum sample was obtained 1 day after one blood culture set yielded C. albicans. Thirteen serum specimens had titers of 1:4; 3 were from colonized patients, and 10 were from patients with disseminated disease. Eleven serum specimens had titers of 1:8; five were from two colonized patients, one with an arterial line contaminated with C. albicans, and six were from patients with deep-seated C. albicans infection. All 10 serum specimens with titers of 1:16 or higher were from patient 3, who had abdominal abscesses with C. albicans, or from patient 6, who had histological evidence of deep-seated infection.
The course of illness for the four patients with deep-seated candidiasis diagnosed premortem is shown in Fig. 1 antigen titers during his first hospitalization indicated deepseated infection. The titer remained high on readmission. Unfortunately, subsequent sera were not obtained. Patient 4 had acute renal failure and fever for more than 3 weeks. On the day of initiation of i.v. amphotericin B therapy, the Candida protein antigen titer was 1:8. By day 10 of therapy, no Candida protein antigens were detectable and kidney function improved. Defervescence occurred on day 1 of therapy, and the patient was afebrile on day 3 of treatment. Except for patient 11, who had an arterial line contaminated with C. albicans, the only colonized patient with Candida protein antigen titers greater than 1:4 was patient 7. Two weeks before her death, C. albicans grew in multiple urine cultures. Serum specimens taken 2 weeks prior to and at death yielded 1:8 titers of Candida protein antigens. There was no clinical suspicion of deep-seated candidiasis, and no C. albicans was found at autopsy.
Twenty-four serum specimens from 24 patients with no C. albicans isolated were tested for circulating candidal protein antigens. Twenty-one serum specimens had no detectable antigens. There was one serum specimen each with a titer of 1:2 or 1:4. One serum specimen had a 1:8 Candida antigen titer and was from a patient with psoriasis exacerbated by secondary infection with S. aureus.
Eighty-one serum specimens obtained from patients with positive Candida cultures were also tested for circulating mannan antigen. They included 13 serum specimens with Candida antigen titers of 1:4 and 19 serum specimens with high titers of -1:8. Mannan antigen was not detected in any of the 81 sera. However, the low Candida mannan antigen control supplied in the LA-Candida Antigen Detection System did agglutinate with the sensitized anti-Candida latex reagent.
DISCUSSION
In this study, we examined whether the presence of circulating antigens differentiated between colonization and systemic candidiasis. The correlation was based on clinical evidence of disease. The CAND-TEC latex reagent detects protein antigens of C. albicans and of other Candida species such as C. stellatoideae, C. tropicalis, and C. parapsilosis. The antigen detected is not mannan, which is a carbohydrate and is heat stable (15). The sera used for detecting circulating Candida antigens must not be heat inactivated or treated in any manner which would result in protein denaturation.
According It was surprising that none of the sera from patients with deep-seated candidiasis in this series had detectable mannan antigen. A possible explanation may be the relative insensitivity of mannan detection. First, mannan levels rarely exceed 100 ng/ml in sera from heavily infected Candida patients (7, 9) . Second, the anti-Candida serum for latex sensitization was prepared only against C. albicans serotype A. We did not determine serotype for our Candida isolates.
It seems unlikely that all deep-seated Candida isolates were serotype B. Third, the mannan test has a 40% sensitivity in determining deep-seated Candida infections in immunocompromised hosts (10, 15 (13) .
Fungal surveillance cultures of urine, stool, and respiratory specimens have reportedly not been helpful in predicting systemic C. albicans disease (13) . The surveillance study consisted of culturing samples from these body sites twice weekly and determining whether colonization at one of the sites correlated with systemic disease. With these criteria, only 7% of the patients persistently colonized with C. albicans for 2 or more weeks had systemic candidiasis (13) . In our study, there was a difference in the number of body sites from which C. albicans was isolated in colonized patients versus those patients clinically diagnosed as having disseminated disease. C. albicans was recovered from three or four body sites in 75% of the patients with systemic disease, whereas the organism was recovered from one or two sites in 76% of the colonized individuals. The most frequent site from which C. albicans was isolated was the respiratory tract. The yeast was recovered from the mouth, sputum, bronchial washing, or throat or a combination of these sites in 16 patients, from urine specimens of 13 patients, from blood samples of 6 patients, from stool samples of 4 patients, and from other sites in 12 patients. A previous report suggested that the isolation of C. albicans from both stool and urine specimens most likely indicated disseminated candidiasis (2); in our study, however, patients 7 and 19 did not have systemic disease.
In conclusion, the latex agglutination test for circulating Candida antigens is useful in differentiating between C. albicans colonization and deep-seated infection. Rarely do uninfected or colonized patients have Candida protein antigen titers greater than 1:4. Since many of the patients in our series were immunosuppressed, this assay also appears to be useful for this patient population.
